J&J cuts 2026 EPS guidance by $0.64 on $1B Firefly Bio acquisition, Sail collaboration

Filed July 29, 2026 · Period ending July 29, 2026 · ~2 min read

Key Changes

• high

  Reduced full-year 2026 adjusted EPS guidance from $11.60-$11.75 to $10.96-$11.11 (midpoint down $0.64 to $11.04), entirely due to Firefly ($0.46) and Sail ($0.18) transactions; growth outlook drops from 7.5%-8.9% to 1.6%-3.0%.

  Item 7.01 — Regulation FD Disclosure verify on EDGAR →
• high

  Completed $1B cash acquisition of Firefly Bio's degrader antibody conjugate platform for KRAS-driven cancers; will record ~$1B IPR&D charge in Q3 2026 and expects $0.46 EPS dilution in 2026, $0.08 in 2027.

  Exhibit 99.1 view on EDGAR →
• high

  Entered collaboration with Sail Biomedicines on in vivo CAR-T therapies: $785M upfront (including $465M equity), up to $140M milestones, plus $2.58B option to acquire; expects $0.18 EPS dilution in 2026, $1.28 in 2027 if option exercised.

  Exhibit 99.2 view on EDGAR →